CAS 7377-08-4: N-(4-Aminobenzoyl)-β-alanine

N-(4-Aminobenzoyl)-beta-alanine is a molecule that was identified in the 1960s and has been used extensively for research purposes. It is a prodrug that is converted to salicylic acid in vivo. The drug has been shown to scavenge reactive oxygen species, inhibit the enzyme catalase, and protect against oxidative damage. N-(4-Aminobenzoyl)-beta-alanine also provides protection against colitis by inhibiting peroxide production and preventing oxidative damage of colon cells. This drug is orally active and may have potential clinical applications for patients with catalase deficiency or peroxide-mediated diseases such as colitis.

Impurity Balsalazide Aminobenzoyl Impurity Applications N-(4-aminobenzoyl)-β-Alanine is a metabolite of BX661A, a therapeutic agent used in the treatment of ulcerative colitis, chemotaxis and reactive oxygen species production in polymorphonuclear leukocyctes. Inhibits lipid peroxidation in large intestinal mucosa after mesenteric ischemia/reperfusion. References Kimura, I. et al.: Arzneimittelforschung., 48, 1007 (1998); Kumamoto, T. et al.: Jpn. J. Pharmacol., 75, 187 (1997);

N-(4-Aminobenzoyl)-β-Alanine

Applications N-(4-Aminobenzoyl-d4)-β-alanine is the labeled analogue of N-(4-Aminobenzoyl)-β-alanine (A593795), a metabolite of BX661A, a therapeutic agent used in the treatment of ulcerative colitis, chemotaxis and reactive oxygen species production in polymorphonuclear leukocyctes. Inhibits lipid peroxidation in large intestinal mucosa after mesenteric ischemia/reperfusion. References Kimura, I. et al.: Arzneimittelforschung., 48, 1007 (1998); Kumamoto, T. et al.: Jpn. J. Pharmacol., 75, 187 (1997);